NGM·Healthcare·$394M·#452 / 520 in Healthcare
RCKT Rocket Pharmaceuticals, Inc.
23HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY36
VALUATION50
GOVERNANCE45
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
5 months
8
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
9.0%
93
< 25% strong
Price / Sales
Market cap relative to trailing revenue
N/A
50
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.0%
24
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.3%
86
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RCKT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RCKT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.